On April 14, the next session of the Progress Reports Valdecilla Program will take place with presentations by Gabriela Veiga Fernández and David Salcines Cuevas.
A new pathophysiological approach to the compression and management of sclerodegenerative aortic stenosis
SPEAKER: Gabriela Veiga Fernández
Gabriela Veiga Fernández obtained her Bachelor's degree in Medicine and Surgery at the University of Oviedo in 2009 and her Bachelor's Degree in Medicine in 2010. Later, after taking the MIR exam, she completed the 5-year residency in Cardiology at the international HUMV, obtaining the title of Cardiologist in 2015. During this period, she spent 4 months at the Institut universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) in the area of Interventional Cardiology.
After completing his residency and until now he works as a FEA of Cardiology at the HUMV having subspecialized and accredited in Hemodynamics and Interventional Cardiology. In addition, she is a clinical simulation instructor at the Center for Medical Simulation in Boston developing teaching courses at the Valdecilla Virtual Hospital.
During these years he has completed several Masters in Clinical Research Methodology, Thromboembolic and Hemodynamic Disease and Endovascular Interventionism. In addition, it participates annually in congresses of its specialty both nationally and internationally with the presentation of research works in its field, having more than 20 articles in prestigious journals indexed in JRC.
Collaborates in 2 NEXTVAL (IDIVAL) projects since 2017: “The “progressive” patient as a new clinical entity in patients with coronary atherosclerosis. Exploratory study on possible molecular substrates” and “Impact on the quality of life and functionality of patients with percutaneous aortic valve implantation versus surgical aortic valve replacement”.
3 years ago he joined the Doctorate program in Medicine and Health Sciences at the University of Cantabria.
New nanovaccines against intracellular pathogens
SPEAKER: David Salcines Cuevas
David Salcines Cuevas obtained his degree as a graduate in Biotechnology in 2015 from the University of Zaragoza. In 2017 he completed a Master in Biology and Molecular Biomedicine from the University of Cantabria.
Since 2018 he has been working as a research support technician in the Oncology and Nanovaccines Group at the Marqués de Valdecilla Research Institute (IDIVAL).
He is co-author of several scientific articles of impact and in the patent "Gold glyconanoparticles conjugated to peptide 1-15 of glyceraldehyde-3-phosphate-dehydrogenase as bacterial vaccines" since 2019.
Due to the current situation, the session will be given in virtual format through the zoom platform. Registration is mandatory to obtain the link to access the session.
Click here for Registration and registration
The session will begin at 14:00. The talk of each speaker will be about 20 minutes followed by a small debate.
Any questions or clarification can be contacted at projects1@idival.org
